We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+10%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$44.5B
AUM Growth
-$1.18B
(-2.6%)
Cap. Flow
-$4.15B
Cap. Flow
% of AUM
-9.34%
Top 10 Holdings %
Top 10 Hldgs %
9.83%
Holding
3,927
New
652
Increased
690
Reduced
847
Closed
1,056
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$309M |
| 2 |
ExxonMobil
XOM
|
+$302M |
| 3 |
Amazon
AMZN
|
+$291M |
| 4 |
Citigroup
C
|
+$253M |
| 5 |
Shopify
SHOP
|
+$238M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$383M |
| 2 |
Johnson & Johnson
JNJ
|
+$312M |
| 3 |
JPMorgan Chase
JPM
|
+$285M |
| 4 |
AT&T
T
|
+$191M |
| 5 |
Dollar General
DG
|
+$187M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.63% |
| 2 | Financials | 15.61% |
| 3 | Technology | 14.28% |
| 4 | Consumer Discretionary | 13.21% |
| 5 | Industrials | 5.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2626
Remitly
RELY
$4.9B
| $232K | ﹤0.01% |
20,240
+600
| +3% | +$6.22K |
|
2627
LiveRamp
RAMP
$2.29B
| $230K | ﹤0.01% |
9,817
-116,538
| -92% | -$2.35M |
|
|
DAO
2628
Youdao
DAO
$1.89B
| $230K | ﹤0.01% |
+42,764
| New | +$185K |
|
2629
Williams-Sonoma
WSM
$27.5B
| $230K | ﹤0.01% |
4,000
-279,072
| -99% | -$16.8M |
|
2630
VictoryShares US EQ Income Enhanced Volatility Wtd ETF
CDC
$750M
| $230K | ﹤0.01% |
+3,700
| New | +$231K |
|
|
VRAY
2631
DELISTED
ViewRay, Inc.
VRAY
| $228K | ﹤0.01% |
50,900
-708,604
| -93% | -$3.08M |
|
|
DHC
2632
Diversified Healthcare Trust
DHC
$2.15B
| $227K | ﹤0.01% |
+349,517
| New | +$345K |
|
2633
iShares MSCI Sweden ETF
EWD
$534M
| $226K | ﹤0.01% |
+7,000
| New | +$219K |
|
2634
Warrior Met Coal
HCC
$4.17B
| $226K | ﹤0.01% |
6,515
-90,568
| -93% | -$3.2M |
|
|
RERE
2635
ATRenew
RERE
$937M
| $226K | ﹤0.01% |
78,067
-24,027
| -24% | -$50.5K |
|
2636
Arcus Biosciences
RCUS
$3.33B
| $225K | ﹤0.01% |
10,896
-6,888
| -39% | -$190K |
|
2637
iShares US Utilities ETF
IDU
$1.37B
| $225K | ﹤0.01% |
+2,600
| New | +$218K |
|
2638
Zebra Technologies
ZBRA
$13.5B
| $225K | ﹤0.01% |
+877
| New | +$227K |
|
|
LL
2639
DELISTED
LL Flooring Holdings, Inc.
LL
| $224K | ﹤0.01% |
+39,781
| New | +$279K |
|
|
ATXS
2640
DELISTED
Astria Therapeutics
ATXS
| $223K | ﹤0.01% |
+14,949
| New | +$154K |
|
2641
Warby Parker
WRBY
$3.19B
| $222K | ﹤0.01% |
+16,458
| New | +$252K |
|
|
SKYAW
2642
CALL
DELISTED
Skydeck Acquisition Corp. Warrants
SKYAW
| $221K | ﹤0.01% |
21,933
| – | – |
|
2643
Hallador Energy
HNRG
$646M
| $220K | ﹤0.01% |
+22,000
| New | +$181K |
|
2644
Weatherford International
WFRD
$5.9B
| $219K | ﹤0.01% |
+4,300
| New | +$177K |
|
2645
Liberty Broadband Class A
LBRDA
$4.89B
| $218K | ﹤0.01% |
+2,875
| New | +$234K |
|
2646
Beyond Air
XAIR
$3.97M
| $218K | ﹤0.01% |
+84
| New | +$215K |
|
2647
Guardant Health
GH
$19.1B
| $217K | ﹤0.01% |
+7,994
| New | +$366K |
|
2648
Werner Enterprises
WERN
$2.2B
| $217K | ﹤0.01% |
+5,400
| New | +$220K |
|
|
PRA
2649
DELISTED
ProAssurance
PRA
| $217K | ﹤0.01% |
+12,420
| New | +$245K |
|
|
SNV
2650
DELISTED
Synovus
SNV
| $217K | ﹤0.01% |
+5,771
| New | +$229K |
|
Similar funds
Marshall Wace's Q4 2022 Portfolio in Review
As of Q4 2022, Marshall Wace held 3,927 positions worth $44.5B, down 2.6% from $45.6B the previous quarter. Its ten largest holdings account for 9.8% of the portfolio.
Marshall Wace withdrew a net $4.15B in Q4 2022, closing 1,056 positions and reducing 847 holdings. Its most notable exit was Humana, an estimated $383M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Financials and Technology.
Against the trend, Marshall Wace opened a new position in Elevance Health worth $188M.
- Marshall Wace's largest Q4 2022 buy was Elevance Health: 366,649 shares worth $188M.
- Marshall Wace added most to Biogen in Q4 2022, an estimated $309M increase.
- Marshall Wace's biggest Q4 2022 reduction was Johnson & Johnson, cutting an estimated $312M.
- Marshall Wace fully exited Humana in Q4 2022, selling an estimated $383M.
- Marshall Wace's ten largest holdings make up 9.8% of its $44.5B portfolio in Q4 2022.
- Marshall Wace opened 652 new positions and closed 1,056 in Q4 2022.
- Marshall Wace's portfolio value fell 2.6% quarter-over-quarter to $44.5B.
Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.